Chemomab Therapeutics CMMB Stock
Chemomab Therapeutics Price Chart
Chemomab Therapeutics CMMB Financial and Trading Overview
| Chemomab Therapeutics stock price | 1.72 USD |
| Previous Close | 2 USD |
| Open | 2.08 USD |
| Bid | 1.79 USD x 100 |
| Ask | 1.92 USD x 100 |
| Day's Range | 1.86 - 2.08 USD |
| 52 Week Range | 1.35 - 5.52 USD |
| Volume | 110.42K USD |
| Avg. Volume | 45.91K USD |
| Market Cap | 13.39M USD |
| Beta (5Y Monthly) | 0.508 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15 USD |
CMMB Valuation Measures
| Enterprise Value | 1.06B USD |
| Trailing P/E | N/A |
| Forward P/E | -62 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2525252 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -135.362 |
Trading Information
Chemomab Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.508 |
| 52-Week Change | -65.29% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 5.52 USD |
| 52 Week Low | 1.35 USD |
| 50-Day Moving Average | 1.68 USD |
| 200-Day Moving Average | 2.24 USD |
CMMB Share Statistics
| Avg. Volume (3 month) | 45.91K USD |
| Avg. Daily Volume (10-Days) | 56.99K USD |
| Shares Outstanding | 7.2M |
| Float | 511.66M |
| Short Ratio | 0.96 |
| % Held by Insiders | 11.49% |
| % Held by Institutions | 8.81% |
| Shares Short | 39.65K |
| Short % of Float | 0.57% |
| Short % of Shares Outstanding | 0.54% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.25% |
| Return on Equity (ttm) | -70.60% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -7855750 USD |
| Net Income Avi to Common (ttm) | -7445000 USD |
| Diluted EPS (ttm) | -1.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.04M USD |
| Total Cash Per Share (mrq) | 0.01 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 10.309 |
| Book Value Per Share (mrq) | 1.485 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Chemomab Therapeutics
| Country | United States |
| State | N/A |
| City | Tel Aviv |
| Address | Building C |
| ZIP | 6158101 |
| Phone | 972 77 331 0156 |
| Website | https://www.chemomab.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Q&A For Chemomab Therapeutics Stock
What is a current CMMB stock price?
Chemomab Therapeutics CMMB stock price today per share is 1.72 USD.
How to purchase Chemomab Therapeutics stock?
You can buy CMMB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chemomab Therapeutics?
The stock symbol or ticker of Chemomab Therapeutics is CMMB.
Which industry does the Chemomab Therapeutics company belong to?
The Chemomab Therapeutics industry is Biotechnology.
How many shares does Chemomab Therapeutics have in circulation?
The max supply of Chemomab Therapeutics shares is 7.2M.
What is Chemomab Therapeutics Price to Earnings Ratio (PE Ratio)?
Chemomab Therapeutics PE Ratio is now.
What was Chemomab Therapeutics earnings per share over the trailing 12 months (TTM)?
Chemomab Therapeutics EPS is -1.12 USD over the trailing 12 months.
Which sector does the Chemomab Therapeutics company belong to?
The Chemomab Therapeutics sector is Healthcare.
Chemomab Therapeutics CMMB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}